Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event
OTTAWA, Ontario, June 12, 2025--(BUSINESS WIRE)--As global trade tensions remain at the forefront of business decision-making, Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern.
Titled, Tariffs, Trade, and Turbulence: How to Respond to Today's Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today's volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains.
"We're witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what's coming next," said Andrew Busch, economic futurist and economist at AndrewBusch.com. "Tariffs are no longer just a policy lever; they're a strategic force reshaping the global economy with rules being rewritten in real time and disruption being the only constant."
Kinaxis is at the forefront of helping companies of all industries and sizes respond to today's tariff disruptions. Its leading AI-powered orchestration platform Maestro™ seamlessly connects all supply chain functions to create visibility, collaboration, and smarter decision making in the face of any disruption. During the U.S. presidential election, there was a dramatic increase in the number of what-if scenarios that companies ran on Maestro as they modeled and actioned potential impacts to sourcing, production, and logistics.
"The practice of supply chain management has fundamentally evolved, and disruptions like tariffs demonstrate the need for a modern approach that emphasizes speed, agility, and precision," said Andrew Bell, chief product officer at Kinaxis. "The speakers joining me during this discussion have made transformative supply chain change and bring first-hand experience around how they are using this new approach to navigate today's complex challenges. I look forward to highlighting their stories and to helping other companies take steps to better prepare their supply chains for today's realities."
Expert guest speakers include:
Andrew Busch, economic futurist and economist, will speak about the geopolitical and economic outlook on tariff policy, including insights into U.S.-China relations, global decoupling, and the future of trade
Brent Wilson, senior vice president global supply chain, Qualcomm will share his experiences navigating tariff-driven disruption and building supply chain resilience
Mark Walker, vice president supply chain, Viant Medical will share his experience strengthening the complex supply chain of Viant Medical through effective planning
Ken Vandrak, senior director, distribution and logistics, Thermo Fisher Scientific will discuss his experience in navigating the evolving trade landscape and overcoming logistical challenges in global distribution
Andrew Bell, chief product officer, Kinaxis will share his perspective on the role of AI, automation, and scenario planning in supply chains to drive faster, smarter decision making
Webinar: Tariffs, Trade, and Turbulence: How to Respond to Today's Supply Chain ChallengesDate: Tuesday, June 17Time: 11:00 AM ETRegistration Link: HERE
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today's volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612438708/en/
Contacts
Media Relations Matt Tatham | Kinaxismtatham@kinaxis.com +1 917.446.7227Investor Relations Rick Wadsworth | Kinaxisrwadsworth@kinaxis.com +1 613-907-7613
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Coloplast A/S – Interim Financial Report, 9M 2024/25
By GlobeNewswire Published on August 19, 2025, 10:33 IST 2024/25 Interim financial results, 9M 2024/25 1 October 2024 – 30 June 2025 Coloplast delivered organic growth of 7% and an EBIT margin1 of 28% in Q3. Reported revenue in DKK grew 1% with negative impact from currencies and the Skin Care divestment. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 4% and Interventional Urology 4%. Growth in Ostomy Care was driven by broad-based contribution across regions, except for China which delivered low-single digit growth, as expected. Growth in Continence Care was driven by continued strong contribution from the Luja™ portfolio. Voice and Respiratory Care growth was driven by continued good momentum in both Laryngectomy and Tracheostomy. Growth in Advanced Wound Dressings was -2%, driven primarily by a significant decline in China which was impacted by a preventative and voluntary product return of all Biatain® Adhesive foam dressings in the market. The product return is expected to have a negative revenue impact of around DKK 80 million in H2, of which around DKK 20 million impacted Q3. Kerecis grew 17%, with a 13% EBIT margin before PPA amortisation. Growth in the quarter was impacted by a slowdown in the out-patient setting due to the LCD postponement in April, causing a temporary market shift to high-priced products. Growth momentum in Q4 is expected to improve, with a good start to the quarter in July. Growth in Interventional Urology was driven by good momentum in the US Men's Health business, partly offset by continued negative impact from the product recall in Bladder Health and Surgery of around DKK -10 million in Q3. EBIT 1 was DKK 1,915 million, a 2% increase from last year. The EBIT margin 1,2 was 28%, against 27% last year. was DKK 1,915 million, a 2% increase from last year. The EBIT margin was 28%, against 27% last year. Changes to the Executive Leadership Team announced, to support the successful execution of the new company strategy towards 2030. 9M 2024/25 organic growth of 7% and EBIT margin1 of 27%. Reported revenue in DKK grew 4% to DKK 20,914 million. Organic growth rates by business area: Ostomy Care 6%, Continence Care 8%, Voice and Respiratory Care 9%, Advanced Wound Care 9% and Interventional Urology 1%. EBIT 1 was DKK 5,718 million, a 4% increase from last year. The EBIT margin 1 was 27%, on par with last year 2 . was DKK 5,718 million, a 4% increase from last year. The EBIT margin was 27%, on par with last year . Adjusted3 net profit before special items was DKK 3,778 million, a DKK 15 million decrease from last year, negatively impacted by non-cash effect from net financial expenses. Adjusted3 diluted earnings per share (EPS) before special items decreased by 1% to DKK 16.76. Adjusted3 ROIC after tax before special items was 15%, on par with last year. FY 2024/25 guidance is unchanged with organic growth of around 7% and an EBIT margin before special items of 27-28%. Organic growth now includes the negative impact from the product return in Advanced Wound Dressings in China, partly offset by good momentum in the other business areas. Reported growth in DKK is now expected to be 3-4%, with around 2%-points negative impact from currencies and around 1.5%-points negative impact from the Skin Care divestment. The assumptions on the reported EBIT margin before special items are largely unchanged. Special items expectations are unchanged, around DKK 450 million. Expectations on capital expenditures and tax rate (ordinary and effective) are also unchanged. 'We deliver a third quarter as expected with 7% organic growth and an EBIT margin of 28%, maintaining our financial guidance for 2024/25. Our Q3 performance was driven by broad-based growth across our chronic care businesses, offsetting the challenges in China. I'm pleased to see the global Coloplast organisation continuing to deliver on our priorities and moving the business forward. The search for Coloplast's new CEO remains on track. I look forward to presenting our 2030 strategy at our Capital Markets Day on 2 September alongside the new Executive Leadership Team, announced today,' says interim CEO Lars Rasmussen. 1. before special items expenses of DKK 83 million in Q3 2024/25 and DKK 241 million in 9M 2024/25. 2. before special items expenses of DKK 36 million in Q3 2023/24 and DKK 70 million in 9M 2023/24. 3. Adjusted for the impact from the Kerecis IP transfer. Conference call Coloplast will host a conference call on Tuesday, 19 August 2025 at 11.00 CEST. The call is expected to last about one actively participate in the Q&A session please sign up ahead of the conference call on the link here to receive an e-mail with dial-in details: Register here Access the conference call webcast directly here: Coloplast – 9M 2024/25 conference call For further information, please contact Investors and analysts Anders Lonning-SkovgaardExecutive Vice President, CFO Tel. +45 4911 1111 Aleksandra DimovskaVice President, Investor RelationsTel. +45 4911 1800 / +45 4911 2458 Email: [email protected] Kristine Husted MunkSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 3266 Email: [email protected] Simone Dyrby HelvindSenior Manager, Investor RelationsTel. +45 4911 1800 / +45 4911 2981 Email: [email protected] Press and media Peter MønsterSr. Media Relations ManagerTel. +45 4911 2623 Email: [email protected] Address Coloplast A/SHoltedam 1DK-3050 HumlebaekDenmark Company reg. (CVR) no. 69749917 Website This announcement is available in a Danish and an English-language version. In the event of discrepancies, the English version shall prevail. Coloplast was founded on passion, ambition, and commitment. We were born from a nurse's wish to help her sister and the skills of an engineer. Guided by empathy, our mission is to make life easier for people with intimate healthcare needs. Over decades, we have helped millions of people to live a more independent life and we continue to do so through innovative products and services. Globally, our business areas include Ostomy Care, Continence Care, Advanced Wound Care, Interventional Urology and Voice and Respiratory Care. The Coloplast logo is a registered trademark of Coloplast A/S. © 2025-08. All rights reserved Coloplast A/S, 3050 Humlebaek, Denmark. Attachment 06_2025_9M_2024_25_Earnings_release Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. Ahmedabad Plane Crash GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Yahoo
4 hours ago
- Yahoo
2 Dirt-Cheap Stocks to Buy With $1,000 Right Now
Written by Rajiv Nanjapla at The Motley Fool Canada Amid the expectation of rate cuts by the Federal Reserve due to easing inflation and solid second-quarter earnings, the S&P/TSX Composite Index has continued its uptrend, rising 12.9% year to date. However, the following two Canadian stocks have failed to impress investors and have lost a substantial percentage of their stock values this year. Given their discounted stock prices and healthy growth prospects, I expect these stocks to outperform over the next three years. Lightspeed Commerce Lightspeed Commerce (TSX:LSPD), which offers omnichannel commerce solutions to businesses worldwide, has been under pressure this year, with the company losing 22% of its stock value. Meanwhile, the company posted a healthy first-quarter performance of fiscal 2026 last month, beating its guidance. Its top line of $304.9 million was higher than its guidance of $285-$290 million. Year over year, its revenue grew 14.6% amid the expansion of customer locations and increased ARPU (average revenue per user). Increased software prices and growing adoption of its payments have increased its ARPU. Meanwhile, the company's net losses rose from $35 million to $49.6 million. Higher direct, general and administrative, research and development, sales and marketing, interest, and tax expenses led to an increase in its net losses. However, its adjusted EBITDA (earnings before interest, tax, depreciation, and amortization) increased by 55.9% to $15.9 million. Further, it ended the quarter with cash and cash equivalents of $447.6 million and is well-equipped to fund its growth initiatives. Amid the expanding e-commerce market, enterprises are adopting an omnichannel selling model, thereby expanding Lightspeed's addressable market. Also, the company is developing and introducing new innovative products and artificial intelligence-powered features to strengthen its position. Moreover, the company's management has reiterated its three-year guidance, with its gross profit and adjusted EBITDA projected to grow at an annualized rate of 15-18% and 35%, respectively. Therefore, the Montreal-based company's growth prospects look healthy. Further, the recent pullback in Lightspeed's stock price has dragged its NTM (next-12-month) price-to-sales multiple down to an attractive 1.4, making it an excellent buy. WELL Health Technologies Another cheap Canadian stock that I am bullish on is WELL Health Technologies (TSX:WELL), which has lost 30.3% of its stock value this year. The ongoing investigation into Circle Medical's billing practices appears to have made investors nervous, dragging its stock price down. However, it reported an excellent second-quarter performance last week with record revenue, adjusted EBITDA, and adjusted net income. Its revenue grew 57% to $356.7 million amid organic growth, acquisitions, and $40.5 million contributions from HEALWELL AI. It had over 1.7 million patient visits during the quarter, with around one million coming from Canada. The tech-enabled healthcare company's adjusted EBITDA rose 231% to $49.7 million during the quarter, while its adjusted EPS (earnings per share) came in at $0.10, representing a significant improvement from $0.02 in its previous year's quarter. Meanwhile, the growing adoption of virtual healthcare services and the digitization of clinical procedures have expanded the addressable market for WELL Health. Meanwhile, the company is developing and launching artificial intelligence-powered products to expand its customer base and strengthen its position. Additionally, the company is continuing with its inorganic expansions and has completed 14 acquisitions year to date. It has signed 15 letters of intent that can contribute $134 million to its annualized revenue. Considering its organic and inorganic growth initiatives, I believe its growth prospects look healthy. Additionally, the company currently trades at 11.3 times analysts' projected earnings for the next four quarters, which looks cheap considering its healthy growth prospects. Considering all these factors, I expect WELL Health to deliver oversized returns over the next three years. The post 2 Dirt-Cheap Stocks to Buy With $1,000 Right Now appeared first on The Motley Fool Canada. Should you invest $1,000 in Shopify right now? Before you buy stock in Shopify, consider this: The Motley Fool Stock Advisor Canada analyst team identified what they believe are the 15 best stocks for investors to buy now… and Shopify wasn't one of them. The 15 stocks that made the cut could potentially produce monster returns in the coming years. Consider MercadoLibre, which we first recommended on January 8, 2014 … if you invested $1,000 in the 'eBay of Latin America' at the time of our recommendation, you'd have $24,427.64!* Now, it's worth noting Stock Advisor Canada's total average return is 94%* – a market-crushing outperformance compared to 61%* for the S&P/TSX Composite Index. Don't miss out on our top 15 list, available when you join Stock Advisor Canada. See the 15 Stocks * Returns as of July 15th, 2025 More reading 10 Stocks Every Canadian Should Own in 2025 3 Canadian Companies Powering the AI Revolution Fool contributor Rajiv Nanjapla has no position in any of the stocks mentioned. The Motley Fool recommends Lightspeed Commerce. The Motley Fool has a disclosure policy. 2025
Business Insider
5 hours ago
- Business Insider
Desjardins Reaffirms Their Buy Rating on Automotive Properties (APR.UN)
Desjardins analyst maintained a Buy rating on Automotive Properties today and set a price target of C$13.00. The company's shares closed today at C$11.59. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. In addition to Desjardins, Automotive Properties also received a Buy from CIBC's Tal Woolley in a report issued today. However, on August 15, RBC Capital maintained a Hold rating on Automotive Properties (TSX: The company has a one-year high of C$12.78 and a one-year low of C$9.04. Currently, Automotive Properties has an average volume of 14.78K.
